An Intervention in a Primary Healthcare Setting to Reduce Lyme Neuroborreliosis Treatment Delay
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Lyme Neuroborreliosis
- Sponsor
- Odense University Hospital
- Enrollment
- 60
- Locations
- 1
- Primary Endpoint
- Number of days from symptom debut to beginning of antibiotic treatment for Lyme neuroborreliosis
- Last Updated
- 7 years ago
Overview
Brief Summary
This study evaluates the effect of written and oral information in a primary health care setting on 1) patients referred to specialised examination for Lyme neuroborreliosis, 2) delay from patient symptom debut to treatment for Lyme neuroborreliosis, and 3) number of Borrelia serology tests from primary health care.
Detailed Description
Lyme neuroborreliosis is among the most common neuroinfections in northern Europe. Residual symptoms after treatment are a frequent problem in Lyme neuroborreliosis, and an association between the delay from symptom debut to antibiotic treatment has been established. In a previous study on Funen Island, Denmark, the delay from day of symptom debut to treatment for Lyme neuroborreliosis patients was 24 days. This considerable treatment delay did not change in the 20 years study period. In the Danish health system, the general practitioners are the first medical professionals to see the majority of patients. They can refer patients to the hospital for further examination if indicated. Many general practitioners use Borrelia burgdorferi antibodies (igM/IgG) as a screening tool when they suspect Lyme disease or see patients with uncharacteristic symptoms. This is unfortunate, as the rash Erythema Migrans, the most common Borreliosis manifestation in Europe, is a clinical diagnosis. Only around 50% of patients have positive antibodies at time of Erythema Migrans diagnosis. Lyme neuroborreliosis is diagnosed based on symptoms and the results from the cerebrospinal fluid, and cannot be diagnosed based on serology, which only delays the time to diagnoses and treatment. The Danish guidelines on Lyme borreliosis therefore discourage general practitioners from using Borrelia serology. In the before mentioned study from Funen Island, several patients described multiple contacts to their general practitioners, where the symptoms of Lyme neuroborreliosis were not recognized. The cardinal symptom of radicular pain was associated with a longer delay than many of the less common symptoms of Lyme neuroborreliosis.
Investigators
Fredrikke Christie Knudtzen
Speciality Registrar, Specialist in Infectious Diseases, Principal Investigator
Odense University Hospital
Eligibility Criteria
Inclusion Criteria
- •Primary care physicians with a postal code in an area of Funen Island with a Lyme neuroborreliosis incidens of \> 4.6/100.000
- •Patients with a postal address on Funen and a positive Borrelia intrathecal antibody test (diagnostic for lyme neuroborreliosis) performed at the Department of Clinical Microbiology, Odense University Hospital from January 1st 2017 - December 31st 2020
- •A Borrelia IgM/IgG serology ordered from Primary Health Care and performed at the Department of Clinical Microbiology, Odense University Hospital from January 1st 2017 - December 31st 2020
Exclusion Criteria
- •Primary care physicians with a postal code in an area of Funen Island with a Lyme neuroborreliosis incidens of \< 4.7/100.000
Outcomes
Primary Outcomes
Number of days from symptom debut to beginning of antibiotic treatment for Lyme neuroborreliosis
Time Frame: 0-90 days
Number of days from debut of neurological symptoms to beginning of antibiotic treatment for Lyme neuroborreliosis.
Secondary Outcomes
- Number of yearly referred Lyme patients(Up to 4 years (1460 days).)
- Number of Borrelia antibody tests in peripheral blood ordered by primary care physicians(Up to 4 years (1460 days).)